Switch theme
Sign up to access all valuation multiples
CStone Pharmaceuticals is engaged in developing and commercializing of immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment.
2015
230
LTM Revenue $59.2M
LTM EBITDA -$22.8M
$642M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CStone Pharmaceuticals has a last 12-month revenue (LTM) of $59.2M and a last 12-month EBITDA of -$22.8M.
In the most recent fiscal year, CStone Pharmaceuticals achieved revenue of $52.0M and an EBITDA of -$3.3M.
CStone Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CStone Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $59.2M | XXX | $52.0M | XXX | XXX | XXX |
| Gross Profit | $59.2M | XXX | $30.7M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | -$22.8M | XXX | -$3.3M | XXX | XXX | XXX |
| EBITDA Margin | -39% | XXX | -6% | XXX | XXX | XXX |
| EBIT | -$25.4M | XXX | -$11.7M | XXX | XXX | XXX |
| EBIT Margin | -43% | XXX | -23% | XXX | XXX | XXX |
| Net Profit | -$15.3M | XXX | -$11.6M | XXX | XXX | XXX |
| Net Margin | -26% | XXX | -22% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, CStone Pharmaceuticals's stock price is HKD 4 (or $1).
CStone Pharmaceuticals has current market cap of HKD 5.4B (or $686M), and EV of HKD 5.0B (or $642M).
See CStone Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $642M | $686M | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, CStone Pharmaceuticals has market cap of $686M and EV of $642M.
CStone Pharmaceuticals's trades at 12.4x EV/Revenue multiple, and -191.7x EV/EBITDA.
Equity research analysts estimate CStone Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CStone Pharmaceuticals has a P/E ratio of -48.8x.
See valuation multiples for CStone Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $686M | XXX | $686M | XXX | XXX | XXX |
| EV (current) | $642M | XXX | $642M | XXX | XXX | XXX |
| EV/Revenue | 11.8x | XXX | 12.4x | XXX | XXX | XXX |
| EV/EBITDA | -30.6x | XXX | -191.7x | XXX | XXX | XXX |
| EV/EBIT | -27.5x | XXX | -54.8x | XXX | XXX | XXX |
| EV/Gross Profit | 11.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -48.8x | XXX | -58.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -14.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCStone Pharmaceuticals's last 12 month revenue growth is 23%
CStone Pharmaceuticals's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
CStone Pharmaceuticals's rule of 40 is -41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CStone Pharmaceuticals's rule of X is 19% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CStone Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Margin | -39% | XXX | -6% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -41% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 19% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 81% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CStone Pharmaceuticals acquired XXX companies to date.
Last acquisition by CStone Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . CStone Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CStone Pharmaceuticals founded? | CStone Pharmaceuticals was founded in 2015. |
| Where is CStone Pharmaceuticals headquartered? | CStone Pharmaceuticals is headquartered in Hong Kong. |
| How many employees does CStone Pharmaceuticals have? | As of today, CStone Pharmaceuticals has 230 employees. |
| Who is the CEO of CStone Pharmaceuticals? | CStone Pharmaceuticals's CEO is Dr. Jianxin Yang, M.D.,PhD. |
| Is CStone Pharmaceuticals publicy listed? | Yes, CStone Pharmaceuticals is a public company listed on HKG. |
| What is the stock symbol of CStone Pharmaceuticals? | CStone Pharmaceuticals trades under 02616 ticker. |
| When did CStone Pharmaceuticals go public? | CStone Pharmaceuticals went public in 2019. |
| Who are competitors of CStone Pharmaceuticals? | Similar companies to CStone Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of CStone Pharmaceuticals? | CStone Pharmaceuticals's current market cap is $686M |
| What is the current revenue of CStone Pharmaceuticals? | CStone Pharmaceuticals's last 12 months revenue is $59.2M. |
| What is the current revenue growth of CStone Pharmaceuticals? | CStone Pharmaceuticals revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of CStone Pharmaceuticals? | Current revenue multiple of CStone Pharmaceuticals is 11.8x. |
| Is CStone Pharmaceuticals profitable? | Yes, CStone Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CStone Pharmaceuticals? | CStone Pharmaceuticals's last 12 months EBITDA is -$22.8M. |
| What is CStone Pharmaceuticals's EBITDA margin? | CStone Pharmaceuticals's last 12 months EBITDA margin is -39%. |
| What is the current EV/EBITDA multiple of CStone Pharmaceuticals? | Current EBITDA multiple of CStone Pharmaceuticals is -30.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
